Related Experiment Video
Updated: Apr 13, 2026
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
Schisantherin A alleviates DSS-induced colitis by upregulating ferredoxin 1 to inhibit inflammation and restore
Hongyu Xiao1, Na Li1, Jiangyan Rao1
1Department of General Surgery, Chongqing General Hospital, Chongqing University, Chongqing, China.
Background:
Ulcerative colitis (UC) is a chronic non-specific inflammatory disease of the intestine with unknown etiology, and its effective treatments are still lacking. Repairing the intestinal mucosal barrier and reducing persistent inflammation is the key strategies for the treatment of UC. Schisantherin A (Sin A), a lignan compound extracted from Schisandra chinensis, exhibits anti-inflammatory, antioxidant, and neuroprotective effects. However, the role and mechanism of Sin A in the treatment of UC remains unclear.
Purpose:
This study aims to investigate the effect of Sin A on UC and elucidate its underlying molecular mechanism.
Methods:
The effect of Sin A on UC was evaluated using a 3 % dextran sulfate sodium (DSS)-induced mouse model. Transcriptome sequencing analysis was performed to preliminarily explore the mechanism of Sin A in colitis. Based on the transcriptome results, the expression of proteins and mRNAs related to the FDX1-PI3K/AKT axis was determined by qPCR, immunofluorescence (IF), and western blotting. Additionally, plasmid transfection, molecular docking, drug affinity responsive target stability (DARTS), and cellular thermal shift assay (CETSA) were employed to verify the interaction between FDX1 and Sin A.
Results:
Sin A can alleviate the clinical symptoms of UC mice, inhibit intestinal inflammation and repair intestinal barrier damage. Both transcriptomic sequencing results and ex vivo experiments confirmed that the therapeutic effect of Sin A on UC is associated with modulation of the FDX1-PI3K/AKT axis. Further studies demonstrated that FDX1 is a critical target for Sin A to inhibit the PI3K/AKT signaling pathway and exert its anti-UC effect.
Conclusion:
This study demonstrates for the first time that Sin A is a potential natural active ingredient for the treatment of UC, as it alleviates UC by suppressing inflammation and preventing barrier disruption. Furthermore, the critical role of the FDX1-PI3K/AKT axis in UC was confirmed, providing a theoretical basis for the application of Sin A.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:21Drugs for Treatment of Constipation-Predominant IBS